Errant Gene Therapeutics'™ strong intellectual property position is the result of acquisition and academic collaborations. The Company's foremost objective is the rapid commercialization of its most advanced technologies. In addtion, EGT continually seeks new sources of products targeting rare disorders.

The lead compound Thalagen™, a treatment for the blood disorder thalassemia, is soon to enter into Phase I human clinical trials. A second product, JW 1521 is nearing completion of pre-clinical development and will be targeted for clinical development as a treatment for chemotherapy resistant prostate cancer.

The following table lists the principal products being developed by the Company:

Please click on the following links for more information on EGT's products in development:

• Thalagen™: Gene Therapy Treatment for thalassemia
• JW 1521: Refractory Prostate Cancer
• Trichostatin A : Active Pharmaceutical Ingredient
• MSKCC product : Sickle Cell Anemia... coming soon